2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-6-[(2,6,6-trimethylcyclohex-2-en-1-yl)methyl]chromen-4-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-6-[(2,6,6-trimethylcyclohex-2-en-1-yl)methyl]chromen-4-one
• 化学式: C₂₅H₂₆O₆
• 分子量: 422.5
• InChiKey: HTXVMYSFROUDJB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  31
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  107
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• Use of helminthostachys, ugonins or flavone-based compounds for the treatment or prevention of metabolic diseases
  申请人：National Research Institute of Chinese Medicine, Ministry of Health and Welfare

  公开号：US10272124B2

  公开（公告）日：2019-04-30

  Disclosed is a use of Helminthostachys zeylanica, ugonins or compounds of formula (I) for the treatment or prevention of metabolic diseases comprising at least one selected from metabolic syndrome, excessive lipid accumulation, obesity, overweight, fatty liver, hepatic steatosis, hepatitis, cirrhosis, liver cancer, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hyperlipoproteinemia, hypercholesterolemia, cardiovascular disease, hyperglycemia, hyperinsulinemia, diabetes mellitus type 2, insulin resistance, insulin disorder, impaired glucose tolerance and a combination thereof.

  所公开的是Helminthostachys zeylanica、ugonins或式（I）化合物用于治疗或预防代谢疾病的用途，这些代谢疾病包括至少一种选自代谢综合征、脂质过度积累、肥胖、超重、脂肪肝、肝硬变、肝炎、肝硬化、肝癌、血脂异常、高脂血症、高甘油三酯血症、高脂蛋白血症、心血管疾病、高血糖、高胆固醇血症的疾病、肝硬化、肝癌、血脂异常、高脂血症、高甘油三酯血症、高脂蛋白血症、高胆固醇血症、心血管疾病、高血糖、高胰岛素血症、2 型糖尿病、胰岛素抵抗、胰岛素紊乱、糖耐量受损及其组合中的至少一种。
• USE OF HELMINTHOSTACHYS ZEYLANICA, UGONINS OR FLAVONE-BASED COMPOUNDS FOR THE TREATMENT OR PREVENTION OF METABOLIC DISEASES
  申请人：National Research Institute of Chinese Medicine, Ministry of Health and Welfare

  公开号：US20170348367A1

  公开（公告）日：2017-12-07

  Disclosed is a use of Helminthostachys zeylanica , ugonins or compounds of formula (I) for the treatment or prevention of metabolic diseases comprising at least one selected from metabolic syndrome, excessive lipid accumulation, obesity, overweight, fatty liver, hepatic steatosis, hepatitis, cirrhosis, liver cancer, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hyperlipoproteinemia, hypercholesterolemia, cardiovascular disease, hyperglycemia, hyperinsulinemia, diabetes mellitus type 2, insulin resistance, insulin disorder, impaired glucose tolerance and a combination thereof.